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Frataxin is a ubiquitous mitochondrial iron-binding protein involved in the biosynthesis of Fe/S clusters and heme. Its deficiency causes
Friedreich's ataxia, a severe neurodegenerative disease. Mitochondrial ferritin is another major iron-binding protein, abundant in the testis and in
sideroblasts from patients with sideroblastic anemia. We previously showed that its expression rescued the defects caused by frataxin deficiency in
the yeast. To verify if this occurs also in mammals, we silenced frataxin in HeLa cells. This caused a reduction of growth, inhibition of the activity
of aconitase and superoxide dismutase-2 and reduction of cytosolic ferritins without alteration of mitochondrial iron content. None of these effects
were evident when silencing was done in cells expressing mitochondrial ferritin. These data indicate that frataxin has some roles in controlling the
balance between different mitochondrial iron pools that are partially in common with those of mitochondrial ferritin.
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Iron is essential for many functions in the cell, but is also
potentially toxic for its capacity to catalyse free radical pro-
duction. Therefore iron homeostasis must be tightly regulated,
particularly in the mitochondria, where the synthesis of heme
and Fe/S clusters (ISC) occurs. The mechanisms of this regu-
lation in the mitochondrion are unclear, and they must involveAbbreviations: ISC, iron sulfur cluster; FRDA, Friedreich's ataxia; Dox,
doxycycline; MtF, mitochondrial ferritin; Mt53, HeLa cell clone expressing the
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dehydrogenase; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium
bromide; SDH, succinate dehydrogenase; SOD2, superoxide dismutase-2;
IRE, Iron Regulatory Element; IRP1, iron responsive protein-1
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(MtF) is probably one of them, since it has ferroxidase activ-
ity and can sequester mitochondrial iron and reduce its toxicity
[1–4]. Another candidate is frataxin, a mitochondrial iron-
binding protein with homologues in eukaryotes and prokaryotes.
In yeast, the deficiency of the frataxin homologue Yfh1p
causes mitochondrial iron accumulation, increased sensitivity
to oxidative damage, depletion of mitochondrial DNA, de-
creased activities of ISC enzymes and impaired respiration
[5]. These may possibly be related to an inhibition of Mn-
superoxide dismutase-2 (SOD2) activity [6]. In the yeast
Yfh1p seems to act as a mitochondrial iron chaperone, which
interacts with members of ISC biosynthesis like Isu and Nfs1
[7], with ferrochelatase [8], with succinate dehydrogenase
(SDH) and the putative electron transfer flavoprotein complex
homologue Etf [9]. Alternatively it may act as an iron storage
protein [10].
Frataxin has been extensively studied because its deficiency
is the cause of Friedreich's ataxia (FRDA), the most common
91I. Zanella et al. / Biochimica et Biophysica Acta 1782 (2008) 90–98genetic ataxia [11]. However, the role of frataxin in mammalian
cells is more complex and controversial than in yeast. Mito-
chondrial iron accumulation is not a common finding in
frataxin-deficient mammalian cells [12], and it occurs in the
heart of mouse models only in the late stage of the disorder
[13]. High sensitivity to oxidative stress has been observed in
frataxin-deficient mammalian cells [14], but not in FRDA mice
models [15]. Frataxin deficiency reduces the activity of
cytosolic ISC proteins [16,17], inducing a phenotype similar
to that caused by the silencing of other proteins of ISC
biosynthesis, such as the cysteine desulfurase Nfs1 [18], and the
Fe/S scaffold protein Isc-U [19]. A direct role of frataxin in ISC
biosynthesis was indicated by its physical interaction with
members of the ISC machinery, including ISD11 [20]. A
reduction of ISC biosynthesis is expected to activate the RNA-
binding activity of the bifunctional protein cytosolic aconitase/
iron regulatory protein-1 and thus repress ferritins and other
iron-binding proteins. In addition, cells from FRDA patients
showed a downregulation of genes involved in sulfur amino
acid metabolism [21] and frataxin deficiency alters heme path-
way transcripts and decreases mitochondrial heme metabolites
in mammalian cells [22–24]. Conversely, frataxin is down-
regulated during erythroid differentiation [25].
MtF is highly expressed in a limited number of cell types
with high metabolic activity [26]. Its overexpression causes
modifications of cytosolic and mitochondrial iron homeostasis
[1–4] and may modify heme biosynthesis. In fact it is abnor-
mally upregulated in the bone marrow cells of sideroblastic
anemia, characterized by mitochondrial iron overload and
defects in heme synthesis [27]. We previously demonstrated the
capacity of human MtF to rescue most of the defects due to the
Yfh1p deficiency in yeast [28]. In the present work we report
that human MtF is likewise able to recover the most evident
effects of frataxin deficiency in human cells. Our data further
support a role of frataxin in the cellular iron homeostasis and
suggest some common functions between MtF and frataxin.
2. Materials and methods
2.1. siRNAs and transient transfections
The ds-siRNAs specific for frataxin were first produced by the method
described in Ref. [29]. The most effective and specific (F3: 5′-GAAAGA-
CUAGCAGAGGAAAC-3′, nt 286–304) was also prepared by chemical
synthesis (Qiagen-Xeragon, Germantown, MD). HeLa Tet-off cells (Clontech
Laboratories, Mountain View, CA) were cultured in Dulbecco's Modified Eagle
Medium (DMEM, Gibco, Invitrogen, Carlsbad, CA) supplemented with 10%
tetracycline-free fetal bovine serum (FBS, Clontech Laboratories), 1 mM l-
glutamine, 40 μg/ml gentamicin and 150 μg/ml hygromicin. The HeLa cell
clone expressing MtF, named Mt53 clone [1], was cultured in DMEM
supplemented with 10% tetracycline-free FBS, 1 mM l-glutamine, 40 μg/ml
gentamicin, 150 μg/ml hygromycin, and 100 μg/ml geneticin without
doxycycline (Dox) to induce the expression of human MtF. Transient
transfections were performed with 100 pmol of siRNAs derived by in vitro
transcription or 50 pmol of synthetic ones in 12-well plates with 2 μl
Oligofectamine (Invitrogen). To extend frataxin silencing up to 5 days, we
performed two sequential transfections at day 0 and again at day 2 and cells were
harvested at day 5. Transfection efficiency was monitored by the use of a
fluorescently labelled unrelated siRNA (Qiagen-Xeragon) and found to be about
90%. All experiments used Oligofectamine alone (mock) and unrelated siRNA
as negative controls.2.2. Stable cell lines
The vector for inducible frataxin silencing was constructed in our laboratory.
It was derived from pEGFP vector (Clontech Laboratories) that constitutively
expresses EGFP under the control of the CMV promoter, and it contained a short
hairpin RNA (sh-RNA) under the control of a human U6 promoter mutagenized
for inducible tetracycline-dependent expression [30]. The F3 sequence was
cloned as sh-RNA downstream of this promoter. T-Rex™ HeLa cell line
stably expressing the Tet repressor from the pcDNA6/TR plasmid (Invitrogen)
was maintained in Minimum Essential Medium with Earle's Salts (E-MEM,
Gibco, Invitrogen) containing 1 mM l-glutamine, 40 μg/ml gentamicin, 5 μg/ml
blasticidin and 10% tetracyclin-free FBS, accordingly to the manufacturer's
instructions. Vector transfection was performed with 5 μl Lipofectamine
(Invitrogen) per μg plasmid DNA. Stable transfectant cells were selected in the
medium containing 400 μg/ml geneticin 48 h after transfection. Resistant clones
were subcultured and analysed for EGFP expression by FACS analysis. The
clones with the strongest expression of EGFP were analysed for frataxin
inducible silencing. Dox induction of the sh-RNA in these cells was performed
at different times (0–15 days) and concentrations (0.5–10 μg/ml) to optimise
silencing. Following optimisation studies, the cells were induced with 7.5 μg/ml
Dox and harvested at day 5.
2.3. Biochemical and immunological methods
L-ferritin levels were determined with a commercial serum ferritin assay
(Abbott Laboratories, Abbott Park, IL). H-ferritin levels were evaluated in total
cellular extracts by an ELISA assay using the monoclonal antibody rH02
calibrated on the recombinant homopolymer [31]. In immunoblot experiments,
equal amounts of proteins were separated on SDS-PAGE and transferred to a
PVDF membrane. The PVDF filters were incubated at 4 °C for 16 h with
specific antibodies: rabbit anti-frataxin polyclonal antibody (1:2000), rabbit
anti-SOD2 polyclonal antibody (1:4000, Upstate, Bilerica, NA), a mouse anti-
MtF polyclonal antibody produced in our laboratory, a rabbit anti-poly
(adenosine diphosphate-ribose) polymerase (anti-PARP) p85 fragment (1:700,
Promega, Madison, WI), a rabbit anti-β-actin monoclonal antibody (1:1000,
Sigma) and anti-voltage-dependent anion channel (VDAC)1/porin antibody
(Sigma). The filters were then washed and further incubated for 1 h with
secondary peroxidase-labelled antibodies, anti-rabbit Ig (Pierce) or anti-mouse
Ig (Dako, Denmark). Immunocomplexes were detected by a chemiluminescence
detection kit (ECL Advance Western Blotting Detection Kit, Amersham
Biosciences, Uppsala, Sweden) with Kodak Image Station 440 CF (Kodak,
Rochester, New York). The densitometric analysis was performed with the
Kodak 1D 3.6 program. For the determination of the activity of aconitase, citrate
synthase, SDH and SOD2 we followed previously described methods [32–35].
When mitochondrial fractionation was required, cells were washed with ice-cold
PBS and resuspended with mitochondrial isolation buffer HMS (220 mM d-
mannitol, 70 mM sucrose, 2 mM HEPES pH 7.4); 1.75 mg/ml digitonin was
added and the cell suspension was incubated for 5 min on ice. The lysed cells
were centrifuged at 11,000 rpm for 6 min to collect the crude mitochondrial
pellet and the post-mitochondrial fraction. The mitochondrial-enriched pellet
was then washed with cold HMS and resuspended in lysis buffer. Absolute
enzyme activities were expressed as mU/mg of protein. For all assays, protein
concentration was determined by the BCA method (Pierce, Rockford, IL),
calibrated on bovine serum albumin (BSA). Free protoporphyrin content was
evaluated by flow cytometry as in [35].
2.4. Real-time quantitative RT-PCR
Total RNAwas extracted with RNAzolB (Tel-Test Inc., Friendswood, Texas,
U.S.A.) according to the manufacturer's instructions and quantified spectro-
photometrically. cDNA synthesis was performed with 1 μg of DNase-treated
RNA using ImProm-II reverse transcriptase (Promega) and oligodT as primer.
Real-time PCR was carried out with PCR primers specific for frataxin mRNA
(sense, 5′-gtggagatctaggaacctatg-3′, and antisense 5′-ttaaggctttagtgagctctg-3′)
and a specific fluorogenic probe (5′-tccagtcataacgcttaggtccac-3′). The sense and
antisense primers were designed to be complementary to regions on two
different exons and the probe to span intron–exon boundaries to avoid
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housekeeping gene glyceradehyde-3-phosphate dehydrogenase (GAPDH) was
used as an endogenous reference. The PCR reaction was carried out using the
GeneAmp™ 5700 Sequence Detection System (Applied Biosystems, Foster
City, CA). Results were normalized to GAPDH levels using the 2−ΔΔCt method.
A value of 1 was given to control samples chosen as calibrators and the sample
values expressed the n-fold reduction of frataxin mRNA with respect to the
calibrator (normalized dose = nd).
2.5. Cell proliferation assays
Cell proliferation was assessed both by trypan blue exclusion assay and by
vital dye reduction with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium
bromide (MTT, Sigma). Briefly, parental and stably transfected cell lines were
seeded in T25 flasks (105 cells per flask) with Dox and cultured for 5 days. At
day 5, cells were trypsinised and viable cells were counted with trypan blue. For
MTT assay, cells were seeded in 24-well plates (5×104 cells per well) with Dox
and cultured for 5 days. At day 5, the medium was removed and replaced with
0.5 ml fresh medium without FBS and with 50 μl MTT solution (5 mg/ml in
PBS) for 2–3 h. The solution was removed and the formazan blue crystals were
dissolved with 1 ml DMSO. The absorbance was read at 570 nm for the
quantification of living metabolically active cells. For transient transfection
experiments, after two rounds of transfection, cells were trypsinised at day 5 and
counted with trypan blue or alternatively were treated for MTT assay as above.
MTT assay was also used to assess sensitivity to oxidative stress: at day 5 post-
induction for stable line and post-transfection for transient silencing, the cells
were washed and incubated in serum-free medium for 1 h. Then cells were
treated with H2O2 (0–1200 μM) for 2 h in serum-free medium, plates were
washed twice with PBS and analysed by incubation with MTT as above. Cells
were also cultured with 0.25 g/l glucose for 3 days or with 1.0 mM ferric
ammonium citrate (FAC) for 18 h prior to assess sensitivity to H2O2 treatment.
For the determination of cell apoptosis, 1×104 cells were plated in 96-well
culture black plates (Corning, Corning, NY) and lysed with the same volume of
Caspase-Glo 3 Assay (Promega) and the luminescence was analysed. The
genomic DNA was extracted according to the protocol for Wizard Genomic
DNA Purification Kit (Promega) and samples were analysed on a 1.5% agarose
gel with ethidium bromide staining.
2.6. [55Fe] uptake
Stable cell lines were grown for 4 days with Dox and then trypsinised,
counted and seeded (2.5×104/well) in 12-well plates with the antibiotic. The day
after, cells were washed twice with PBS and grown for an additional day with
0.5% tetracycline-free FBS, 0.5% BSA, with or without Dox and in the presence
of 74 kBq/ml [55Fe] FAC and 200 μM ascorbic acid. Cells were then washed 3
times with PBS and harvested. After the preparation of extracts, 10 μl of each
sample was mixed with 1 ml scintillation liquid (Ready Safe, Beckman Coulter,
Fullerton, CA) and counted in a liquid scintillation counter. Data were nor-
malized with protein content. Equal amounts of protein extracts (10 μg) wereFig. 1. Efficiency of the F3 siRNA. A: HeLa cells were transfected with 25–100 pmo
time RT-PCR 24 h after transfection. The results were expressed as percentage of the
frataxin levels by Western blot 72 h after transfection. Cell lysates (20 μg total protein
for frataxin and actin. Scr.: scrambled siRNA; m-fxn: mature form of frataxin (17 kDa
extracts [10].separated on 7% non-denaturing PAGE and the dried gels were exposed to
autoradiography. The intensity of ferritin bands was quantified by densitometry
in the linear range.
2.7. Statistical analysis
Statistical analysis was performed using Student's t test for unpaired data.
Values were considered significant when pb0.05.
3. Results
3.1. Frataxin silencing in HeLa cells
To determine the most evident effects of frataxin deficiency,
we initially produced by in vitro transcription 4 different ds-
siRNAs. All of them induced significant silencing of frataxin
mRNA (down to 25%) and protein (down to 10%) in HeLa cells
at 72 h post-transfection (not shown). One of them, coded F3,
was produced by chemical synthesis and used at 25–100 pmol
per well for maximal inhibition of frataxin (Fig. 1). Frataxin
protein level remained below 25% at 72 h post-transfection, a
level below that found in FRDA patients. This caused a reduc-
tion of cell proliferation, which became more evident after a
second sequential transfection to extend silencing up to 5 days
(see below). For a better characterization of the phenotype we
chose to establish HeLa clones with inducible expression of sh-
RNA. To this aim we constructed a vector in which the human
U6 promoter was mutagenized for being controlled by tetra-
cycline and located upstream of a sh-RNA for the F3 sequence.
This vector, named sh-RNA F3, expressed also EGFP under the
control of CMV promoter to facilitate cell selection. It was used
to transfect T-Rex™ HeLa cells expressing the Tet repressor,
and the clones were selected initially with geneticin and for
EGFP expression and then analysed for frataxin level after
incubation with Dox. In different clones Dox caused a dose-
dependent suppression of frataxin at concentrations between 1
and 10 μg/ml (not shown). One clone named F3 clone was
chosen and further characterized. Its frataxin mRNAwas down
to about 20% after 5 days of growth in 5 μg/ml Dox, and below
5% in 7.5 μg/ml Dox (Fig. 2A). Frataxin protein was essentially
undetectable in 7.5 μg/ml Dox at day 5 and remained so until
day 11 (Fig. 2B). The following experiments were done in
7.5 μg/ml Dox and the cells analysed at day 5.l of synthetic F3 siRNA and the level of frataxin mRNAwas quantified by real-
control mock-transfected cells. B: The same transfected cells were analysed for
s) were loaded on 12% SDS-PAGE and immunoblotted with specific antibodies
); d-fxn: frataxin cleavage product (about 14 kDa) also identified in mouse heart
Fig. 2. F3 sh-RNA induction in the F3 clone. A: Stable F3 clone (empty bars) was induced with 1–10 μg/ml of Dox for 5 days and compared to parental line (solid
bars). Frataxin mRNA levels were analysed by real-time RT-PCR and expressed as percentage of the control cells. B: The same clone was analysed for frataxin levels
by immunoblot after 5 and 11 days in the presence or absence of 7.5 μg/ml Doxycycline (Dox). Cell lysates (20 μg total proteins) were loaded on 12% SDS-PAGE and
immunoblotted with the specific antibodies.
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proliferation rate
In the experiments we used as a control the parental T-Rex™
HeLa cells treated with the same Dox concentration. We ini-
tially observed that F3 clone always took a longer time to reach
confluence, then to quantify proliferation we analysed theFig. 3. Phenotype of the stably silenced F3 clone. After 5 days of growth in 7.5 μ
A: Viable cells were counted by trypan blue exclusion assay. Trypan blue stained onl
the dye in comparison with the control cells. Mean of 10 experiments. B: The level o
mg of proteins. Mean and SD of 4 experiments. C: The level of aconitase activity in th
Mean and SD of 5 experiments. D: The mitochondrial fraction was separated and mito
of the control. Mean and SD of 5 experiments. E: The level of citrate synthase activity
proteins. Mean and SD of 5 experiments. The asterisks indicate a significant differe
analysed by immunoblot. β-actin was used for normalization. Representative of 3 i
cellular homogenates was analysed by nitro blue tetrazolium staining of non-denatur
stain was used for normalization of enzyme activity and β-actin was used for normnumber of viable cells after 5 days of growth. Unviable, trypan
blue positive cells were a minor proportion (b5%) in the F3 and
parental clone. The total viable cells in the F3 clone were about
40% of the control (Fig. 3A). Similar results were obtained
when cell proliferation was evaluated by MTT assay or by
protein content (not shown). We observed that the F3 clone had
an altered morphology, with roundish and grainy cells thatg/ml Dox, HeLa T-Rex (solid bars) and F3 clone (empty bars) were analysed.
y b5% of cells, and the data were expressed as percentage of cells that excluded
f SDH activity in total cellular homogenates was analysed and expressed as mU/
e total cellular homogenates was evaluated and expressed as mU/mg of proteins.
chondrial aconitase activity was measured. Results were expressed as percentage
(CS) in the total cellular homogenates was analysed and expressed as mU/mg of
nce (⁎⁎pb0.01, ⁎pb0.05). Porin protein levels in the total cellular lysates were
ndependent experiments with similar results. F: The SOD2 activity in the total
ing PAGE. SOD2 protein levels were analysed by immunoblot. Coomassie blue
alization of protein blotting.
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not seen in the parental cells in the same conditions, but analysis
of PARP fragmentation, caspase-3 activation and DNA lad-
dering did not reveal evident signs of apoptosis (not shown).
3.3. Frataxin deficiency reduces the activity of mitochondrial
enzymes
We analysed two ISC containing enzymes known to be
inhibited by frataxin deficiency [13,16]. In the F3 clone the
activity of succinate dehydrogenase (SDH) decreased to about
60% of the control (Fig. 3B), that of total aconitase to about
45% (Fig. 3C), with a similar decrease in the mitochondrial
(∼51%, Fig. 3D) and cytosolic fractions (∼56%, not shown).
Also citrate synthase (CS) activity slightly decreased in F3
clone without a parallel decrease in porin protein level, as
detected by Western blot (Fig. 3E). Since porin is an index of
mitochondrial content, the result suggests that frataxin depletion
has a negative effect also on non-ISC mitochondrial enzymes.
Treatments for 18 h with H2O2 concentrations up to 1.2 mM
caused a similar reduction of cell viability in the F3 and the
parental clone, even after iron supplementation (1 mM ferric
ammonium sulphate, FAC, for 18 h), but the reduction of
glucose content of the medium from 1 g/l to 0.25 g/l caused a
minor increase of H2O2 toxicity in the F3 clone compared to the
control (not shown), possibly related to enhanced oxidative
phosphorylation. A decrease of the activity of the mitochondrial
superoxide dismutase-2 (SOD2) has been reported in cellular
[14] and animal FRDA models [15]. Total homogenates of the
F3 clone were separated on non-denaturing PAGE and SOD2
activity was developed. This was largely decreased (Fig. 3F),
but SOD2 protein level detected by immunoblot was unchanged
(Fig. 3F), indicating enzyme inactivation.
3.4. Modification of indices of iron status
To study intracellular iron distribution we incubated the cells
with [55Fe] FAC, following the recent observation that also non-
transferrin bound iron is readily delivered to the mitochondria in
cultured cells [1,36]. The mitochondrial fraction was separated,Fig. 4. Iron indices. A: After 5 days of growth in 7.5 μg/ml Dox, parental cells and
radioactivity of the mitochondrial fraction and of the total cellular extracts was count
values. Mean and SD of 5 experiments. B: The total extracts were separated on non-
analyse protein-bound [55Fe]. The single evident band corresponds to cytosolic [55F
total homogenates of T-Rex (solid bars) and F3 clone (empty bars) and the data expres
asterisks indicate significant differences (⁎pb0.05).its specific radioactivity and that of the total homogenates were
counted and expressed as their ratio. They were analogous in the
F3 clone and parental cells (Fig. 4A) indicating that frataxin
deficiency did not cause mitochondrial iron accumulation.
Autoradiography of total cell homogenates run on non-dena-
turing PAGE showed a single band corresponding to cytosolic
ferritin iron, whose intensity was lower in F3 clone than in
control cells (Fig. 4B). ELISA assays confirmed that the level
of cytosolic ferritin protein was lower in F3 clone, both the
L-ferritin (Fig. 4C) and the H-ferritin (not shown). Thus, ferritin
and iron homeostasis were altered in frataxin-deficient cells,
possibly as a consequence of the increased RNA-binding activ-
ity of c-Aconitase/Irp1.
3.5. Mitochondrial ferritin rescues defects of frataxin depleted
HeLa cells
Mitochondrial ferritin (MtF) has a cytoprotective role in
mammalian cells [2] and its expression rescued the defects
associated with frataxin deficiency in yeast [28]. Therefore it
was of interest to evaluate if the same occurs also in mammalian
cells. Initial experiments showed that transfection of the F3
clone with MtF cDNA was difficult, probably because Dox
interferes with transfection or reduces the resistance to the stress
of transfection. Thus, we chose to transiently transfect with F3
siRNA the HeLa cell line that expresses human MtF in the
absence of Dox (clone Mt53) [1]. We performed two sequential
transfections with F3 siRNA to silence frataxin for 5 days and
have a more evident phenotype. Frataxin protein level was
comparable in the parental and Mt53 clone and similarly
decreased after silencing (Fig. 5B). The silencing in control
HeLa cells caused a significant decrease in cell proliferation
(35%, Fig. 5A), in cytosolic H-ferritin level (20%, Fig. 5B), in
total (20%, Fig. 5C) and in mitochondrial aconitase activity
(40%, Fig. 5D). The effects were similar although less evident
than those detected with stable silencing described above. In
contrast, neither of these parameters was modified by the
transient frataxin silencing in the Mt53 clone overexpressing
MtF (Fig. 5A–D). Also the activity of citrate synthase was
slightly reduced by F3 transfection in HeLa cells but not in theF3 clone were incubated for 18 h with 74 kBq/ml [55Fe] FAC, and the specific
ed (cpm/μg of protein). Results were then expressed as the ratio between the two
denaturing PAGE (10 μg of protein per lane) and exposed to autoradiography to
e] ferritin. C: After Dox induction the L-ferritin content (FTL) was evaluated in
sed as ng of ferritin per mg of total proteins. Mean and SD of 4 experiments. The
Fig. 5. Frataxin silencing in the presence of mitochondrial ferritin. Two sequential transient transfections were performed with F3 siRNA to silence frataxin in the HeLa
cell clone expressing mitochondrial ferritin (Mt53) and in parental control cells. A: Cell proliferation was monitored by trypan blue exclusion assay. Trypan blue
stained only b5% of cells in all clones. The data are expressed as percentage of total viable cells in comparison with mock-transfected cells. Mean of 5 experiments.
B: Western blot with anti-frataxin and with anti-MtF polyclonal antibody (which cross-reacts with cytosolic H-ferritin) of the total cellular extracts (20 μg per lane).
β-actin was used for normalization. Representative of 3 independent experiments with similar results. C: Levels of aconitase activity in the total cellular homogenates.
Data were expressed as mU/mg of proteins. Mean and SD of 5 experiments. D: The mitochondrial fraction was separated and aconitase activity was evaluated and
expressed as percentage of the control. Mean and SD of 5 experiments. E: SOD2 activity was analysed by nitro blue tetrazolium staining of non-denaturing PAGE.
Densitometric analyses were normalized with Blue Coomassie stain and expressed as percentage of the control. Mean and SD of 4 experiments. F: The levels of
protoporphyrin were analysed for its intrinsic fluorescence by flow cytometry. Data were expressed as percentage of the mock-transfected cells. Mean and SD of 4
experiments. The asterisks indicate significant differences (⁎pb0.05).
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shown). The activity of SOD2 was significantly reduced in the
silenced control cells in conditions of low glucose content
(0.25 g/l) to force aerobic metabolism, but not in the Mt53 clone
grown in the same conditions (Fig. 5E). An alteration of heme
synthesis in HeLa cells may result in a modification of free
protoporphyrin level, which can be evaluated by its intrinsic
fluorescence. The basal level of fluorescence in the control
HeLa cells was low, but increased of about 40% after frataxin
silencing. Interestingly this did not occur in Mt53 clone, where
frataxin silencing did not have any evident effect on proto-
porphyrin fluorescence (Fig. 5F). Altogether our resultsstrongly suggest that MtF expression in HeLa cells inhibits all
the major effects associated with frataxin silencing.
4. Discussion
4.1. Characterization of frataxin-deficient clone
The present work shows that transient and stable frataxin
silencing in HeLa cells causes a significant reduction of SDH
and cytosolic and mitochondrial aconitase activity, of cytosolic
ferritin and of cell proliferation, in agreement with previous
data [16]. Similar effects in mammalian cells were shown to be
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in the ISC biogenesis, like the ISC transporter ABCB7 [35], the
cysteine desulfurase m-Nfs1 [18] and the protein scaffold Isc-U
[19]. This further supports that frataxin is involved in ISC
biosynthesis in mammals, and consequently has a role in cellular
iron homeostasis. For example, the inhibition of cytosolic ISC
biosynthesis reduces the cytosolic aconitase/Irp1 activity and at
the same time increases its RNA-binding activity, resulting in
the suppression of some IRE containing transcripts, including
the ferritin ones. Although the downregulation of ferritin has
not been observed before, the activation of IRPs RNA-binding
activity was described in frataxin-deficient mammalian cells [16],
inDrosophila cells [37] and also in Nfs1 and Isc-U silenced cells
[19,38].
To evaluate mitochondrial iron content, the cells were
incubated with radioactive FAC, which was readily incorporated
in the mitochondria of cells overexpressing MtF [1] or deficient
in the transporter ABCB7 [35]. In addition, non-transferrin-
bound iron was readily taken up by the mitochondria in cultured
myocytic cells [36], confirming that this form of iron supple-
mentation is regulated by the mitochondria similarly to the more
physiological transferrin iron. Using this approach we could not
detect an increase of mitochondrial iron in the silenced cells. The
finding is in agreement with other studies [12,16] and with the
finding that in mouse models mitochondrial iron accumulation
occurs late in the disease [13]. This stresses the differences in
iron homeostasis between mammalian and yeast cells, where
defects in frataxin invariably cause mitochondrial iron deposi-
tion [5,8]. The lack of evident mitochondrial iron deposition
supports the hypothesis that the decrease in cytosolic ferritin iron
and protein level is more likely due to the defect in cytosolic ISC
proteins such as cytosolic aconitase/IRP1, as mentioned above,
than to iron sequestration in the mitochondria, as found to occur
after MtF expression [1].
The reduction of growth is an effect of frataxin deficiency
shared by mammalian and yeast cells. This suggests that critical
ISC enzymes like yeast Rli1p [39] are involved in the
proliferation also of mammalian cells [17]. Alternatively this
effect could be attributed to an iron detoxification function of
frataxin that in yeast preserved cell longevity [40].
The role of oxidative stress in frataxin deficiency is still
controversial and the FRDA animal model showed a decrease of
SOD2 activity without other evident signs of oxidative damage
[15]. We also observed a decrease in SOD2 activity in the
silenced cells that was expected to reduce antioxidant protec-
tion. However, the cellular model showed a slightly higher
sensitivity to H2O2 toxicity only after forcing aerobic
metabolism by limiting glucose availability, probably because
HeLa cells use only marginally the oxidative metabolism under
normal condition of culture. Similarly, the phenotypic effect of
frataxin deficiency in yeast becomes more evident when cells
are grown in aerobic conditions [41].
4.2. Frataxin deficiency and MtF expression
From the characterization of the F3 clone we concluded that
robust indices of frataxin silencing consisted in the reduction ofcell proliferation, of ferritin levels, of aconitase and of SOD2
activity. They were significantly modified after two rounds of
F3 siRNA transfection in HeLa cells although not as strongly as
in the F3 clone, probably because of the less continuous level of
silencing and the absence of Dox. This allowed us to evaluate if
MtF expression can protect HeLa cells from frataxin deficiency,
as it was shown to occur in yeast cells [28]. We found that
frataxin silencing in a clone expressing MtF did not cause
inhibition of cell growth, reduction of ferritin level, of aconitase
and SOD2 activities. Also free protoporphyrin level, which was
increased in the silenced parental HeLa cells, was not affected
by the silencing in the ones expressing MtF. Thus, MtF inhib-
ited all the detectable effects associated with frataxin silencing
in HeLa cells.
The only known function of MtF is to interact with Fe(II) and
sequester it, thus reducing iron excess. However, MtF has never
been detected in cultured mammalian cells, and when expressed
it reduced cytosolic iron availability [1,3], cell proliferation in
cancer cells [4], and protected the cells from oxidative damage
[2]. Frataxin too has ferroxidase activity and binds Fe(II) in
vitro [42] and, unlike MtF, is ubiquitously expressed in cultured
cells. Thus frataxin deficiency may affect the iron redox status
and reduce iron-sequestering and detoxification activity inside
the mitochondrion [40]. This may possibly cause a deregulation
of the mitochondrial iron pools without alteration of the total
mitochondrial iron. For example, frataxin-deficient mammalian
cells showed an increase of filterable, but not of total iron in the
mitochondria [43]. Possibly more intriguing was the decrease of
SOD2 activity [14,15], which we confirmed. It was proposed
that the mitochondria contain a distinct iron pool that competes
with Mn for SOD2 binding and inactivates the enzyme [35,44].
Thus, SOD2 activity is an index of this “SOD2 reactive” iron
pool, which in yeast increased in the absence of Mtm1p, of
Ssq1, and of Grx5, proteins required for ISC assembly [44]. The
pool increased also after ABCB7 silencing in HeLa cells [35].
In all these models its expansion was accompanied by increased
mitochondrial iron deposition, unlike the present frataxin-
deficient model. The increase of PPIX was another index of
abnormal mitochondrial iron homeostasis in the frataxin-silenced
cells. Individuals with FRDA have increased free protoporphyrin
levels, but without evident signs of erythropoietic defects [45].
Moreover deficient heme synthesis was described in frataxin-
deficient mammalian cells [23] and frataxin was described to act
as an iron chaperone for ferrochelatase [46]. Altogether our data
suggest that in HeLa cells frataxin deficiency may alter the
balance between various iron pools, including the one available to
heme synthesis. MtF may restore the balance, since it reduced the
“SOD2 reactive” pool and increased that available for heme
synthesis. Similar effects were observed inABCB7-deficient cells
[35]. These findings confirm that frataxin is involved in mito-
chondrial iron handling and possibly also in oxidative damage
via the regulation of SOD2 activity, and indicate that it can be
partially substituted by MtF.
In conclusion, the finding that MtF expression inhibits
the effects of frataxin suppression in HeLa cells confirms the
hypothesis that they have some common functions, such as
iron binding and ferroxidation. This may help to interpret the
97I. Zanella et al. / Biochimica et Biophysica Acta 1782 (2008) 90–98unexpected finding that MtF overexpression in tumor cells
strongly suppressed the expression of frataxin protein [4],
although we show that this does not occur in HeLa cells. If the
tight connection between frataxin and the regulation of cellular
iron homeostasis observed in the HeLa cell model occurs also in
the neuronal and cardiac cell types affected in FRDA, the
findings may be of importance for disease treatment.
Acknowledgements
We are grateful to Dr. Franco Taroni for the kind gift of the
rabbit anti-frataxin antibody and Dr. Sonia Levi for the Mt53
cell line. The work was partially supported by Murst-Cofin-
2006 to PA and by grant R0331 of Fondazione Mariani to PA.
References
[1] B. Corsi, A. Cozzi, P. Arosio, J. Drysdale, P. Santambrogio, A. Campanella,
G. Biasiotto, A. Albertini, S. Levi, Human mitochondrial ferritin expressed
in HeLa cells incorporates iron and affects cellular iron metabolism, J. Biol.
Chem. 277 (2002) 22430–22437.
[2] S. Levi, P. Arosio, Mitochondrial ferritin, Int. J. Biochem. Cell Biol. 36
(2004) 1887–1889.
[3] G. Nie, A.D. Sheftel, S.F. Kim, P. Ponka, Overexpression of mitochondrial
ferritin causes cytosolic iron depletion and changes cellular iron home-
ostasis, Blood 105 (2005) 2161–2167.
[4] G. Nie, G. Chen, A.D. Sheftel, K. Pantopoulos, P. Ponka, In vivo tumor
growth is inhibited by cytosolic iron deprivation caused by the expression
of mitochondrial ferritin, Blood 108 (2006) 2428–2434.
[5] U. Muhlenhoff, N. Richhardt, M. Ristow, G. Kispal, R. Lill, The yeast
frataxin homolog Yfh1p plays a specific role in the maturation of cellular
Fe/S proteins, Hum. Mol. Genet. 11 (2002) 2025–2036.
[6] V. Irazusta, E. Cabiscol, G. Reverter-Branchat, J. Ros, J. Tamarit,
Manganese is the link between frataxin and iron–sulfur deficiency in the
yeast model of Friedreich ataxia, J. Biol. Chem. 281 (2006) 12227–12232.
[7] J. Gerber, U. Muhlenhoff, R. Lill, An interaction between frataxin and Isu1/
Nfs1 that is crucial for Fe/S cluster synthesis on Isu1, EMBORep. 4 (2003)
906–911.
[8] Y. Zhang, E.R. Lyver, S.A. Knight, E. Lesuisse, A. Dancis, Frataxin and
mitochondrial carrier proteins, Mrs3p and Mrs4p, cooperate in providing
iron for heme synthesis, J. Biol. Chem. 280 (2005) 19794–19807.
[9] P. Gonzalez-Cabo, R.P. Vazquez-Manrique, M.A. Garcia-Gimeno, P. Sanz,
F. Palau, Frataxin interacts functionally with mitochondrial electron
transport chain proteins, Hum. Mol. Genet. 14 (2005) 2091–2098.
[10] P. Cavadini, H.A. O'Neill, O. Benada, G. Isaya, Assembly and iron-
binding properties of human frataxin, the protein deficient in Friedreich
ataxia, Hum. Mol. Genet. 11 (2002) 217–227.
[11] M. Pandolfo, Iron and Friedreich ataxia, J. Neural. Transm., Suppl. 70 (2006)
143–146.
[12] B. Sturm, U. Bistrich, M. Schranzhofer, J.P. Sarsero, U. Rauen, B.
Scheiber-Mojdehkar, H. de Groot, P. Ioannou, F. Petrat, Friedreich's
ataxia, no changes in mitochondrial labile iron in human lymphoblasts and
fibroblasts: a decrease in antioxidative capacity? J. Biol. Chem. 280 (2005)
6701–6708.
[13] H. Puccio, D. Simon, M. Cossee, P. Criqui-Filipe, F. Tiziano, J. Melki, C.
Hindelang, R. Matyas, P. Rustin, M. Koenig, Mouse models for Friedreich
ataxia exhibit intramitochondrial cardiomyopathy, sensory nerve defect
and Fe–S enzyme deficiency followed by iron deposits, Nat. Genet. 27
(2001) 181–186.
[14] K. Chantrel-Groussard, V. Geromel, H. Puccio, M. Koenig, A. Munnich,
A. Rotig, P. Rustin, Disabled early recruitment of antioxidant defenses in
Friedreich's ataxia, Hum. Mol. Genet. 10 (2001) 2061–2067.
[15] H. Seznec, D. Simon, C. Bouton, L. Reutenauer, A. Hertzog, P. Golik, V.
Procaccio, M. Patel, J.C. Drapier, M. Koenig, H. Puccio, Friedreich ataxia:
the oxidative stress paradox, Hum. Mol. Genet. 14 (2005) 463–474.[16] O. Stehling, H.P. Elsasser, B. Bruckel, U. Muhlenhoff, R. Lill, Iron–sulfur
protein maturation in human cells: evidence for a function of frataxin,
Hum. Mol. Genet. 13 (2004) 3007–3015.
[17] A.Martelli,M.Wattenhofer-Donze, S. Schmucker, S. Bouvet, L. Reutenauer,
H. Puccio, Frataxin is essential for extramitochondrial Fe–S cluster proteins
in mammalian tissues, Hum. Mol. Genet. 16 (2007) 2651–2658.
[18] A. Biederbick, O. Stehling, R. Rosser, B. Niggemeyer, Y. Nakai, H.P.
Elsasser, R. Lill, Role of human mitochondrial Nfs1 in cytosolic iron–
sulfur protein biogenesis and iron regulation, Mol. Cell. Biol. 26 (2006)
5675–5687.
[19] W.H. Tong, T.A. Rouault, Functions of mitochondrial ISCU and cytosolic
ISCU in mammalian iron–sulfur cluster biogenesis and iron homeostasis,
Cell Metab. 3 (2006) 199–210.
[20] Y. Shan, E. Napoli, G. Cortopassi, Mitochondrial frataxin interacts with
ISD11 of the Nfs1/ISCU complex and multiple mitochondrial chaperones,
Hum. Mol. Genet. 16 (2007) 929–941.
[21] G. Tan, E. Napoli, F. Taroni, G. Cortopassi, Decreased expression of genes
involved in sulfur amino acid metabolism in frataxin-deficient cells, Hum.
Mol. Genet. 12 (2003) 1699–16711.
[22] C. Lu, G. Cortopassi, Frataxin knockdown causes loss of cytoplasmic
iron–sulfur cluster functions, redox alterations and induction of heme
transcripts, Arch. Biochem. Biophys. 457 (2007) 111–122.
[23] R.A. Schoenfeld, E. Napoli, A. Wong, S. Zhan, L. Reutenauer, D. Morin,
A.R. Buckpitt, F. Taroni, B. Lonnerdal, M. Ristow, H. Puccio, G.A.
Cortopassi, Frataxin deficiency alters heme pathway transcripts and
decreases mitochondrial heme metabolites in mammalian cells, Hum. Mol.
Genet. 14 (2005) 3787–3799.
[24] E. Napoli, F. Taroni, G.A. Cortopassi, Frataxin, iron–sulfur clusters, heme,
ROS, and aging, Antioxid. Redox Signal. 8 (2006) 506–516.
[25] E.M. Becker, J.M. Greer, P. Ponka, D.R. Richardson, Erythroid
differentiation and protoporphyrin IX down-regulate frataxin expression
in Friend cells: characterization of frataxin expression compared to
molecules involved in iron metabolism and hemoglobinization, Blood 99
(2002) 3813–3822.
[26] P. Santambrogio, G. Biasiotto, F. Sanvito, S. Olivieri, P. Arosio, S. Levi,
Mitochondrial ferritin expression in adult mouse tissues, J. Histochem.
Cytochem. 55 (2007) 1129–1137.
[27] M. Cazzola, R. Invernizzi, G. Bergamaschi, S. Levi, B. Corsi, E. Travaglino,
V. Rolandi, G. Biasiotto, J. Drysdale, P. Arosio, Mitochondrial ferritin
expression in erythroid cells from patients with sideroblastic anemia, Blood
101 (2003) 1996–2000.
[28] A. Campanella, G. Isaya, H.A. O'Neill, P. Santambrogio, A. Cozzi, P.
Arosio, S. Levi, The expression of human mitochondrial ferritin rescues
respiratory function in frataxin-deficient yeast, Hum. Mol. Genet. 13
(2004) 2279–2288.
[29] O. Donzé, D. Picard, RNA interference in mammalian cells using siRNAs
synthesized with T7 RNA polymerase, Nucleic Acids Res. 30 (2002) e46.
[30] J. Ohkawa, K. Taira, Control of the functional activity of an antisense RNA
by a tetracycline-responsive derivative of the human U6 snRNA promoter,
Hum. Gene Ther. 11 (2000) 577–585.
[31] A. Cozzi, S. Levi, E. Bazzigaluppi, G. Ruggeri, P. Arosio, Development of
an immunoassay for all human isoferritins, and its application to serum
ferritin evaluation, Clin. Chim. Acta 184 (1989) 197–206.
[32] P.R. Gardner, D.D. Nguyen, C.W. White, Aconitase is a sensitive and
critical target of oxygen poisoning in cultured mammalian cells and in rat
lungs, Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 12248–12252.
[33] P. Munujos, J. Coll-Canti, F. Gonzalez-Sastre, F.J. Gella, Assay of
succinate dehydrogenase activity by a colorimetric-continuous method
using iodonitrotetrazolium chloride as electron acceptor, Anal. Biochem.
212 (1993) 506–509.
[34] J.R. Williamson, B.E. Corkey, Assay of citric acid cycle intermediates and
related compounds — update with tissue metabolite levels and
intracellular distribution, Methods Enzymol. 55 (1979) 200–222.
[35] P. Cavadini, G. Biasiotto, M. Poli, S. Levi, R. Verardi, I. Zanella,
M. Derosas, R. Ingrassia, M. Corrado, P. Arosio, RNA silencing of the
mitochondrial ABCB7 transporter in HeLa cells causes an iron-deficient
phenotype with mitochondrial iron overload, Blood 109 (2007)
3552–3559.
98 I. Zanella et al. / Biochimica et Biophysica Acta 1782 (2008) 90–98[36] M. Shvartsman, R. Kikkeri, A. Shanzer, Z.I. Cabantchik, Non-transferrin-
bound iron reaches mitochondria by a chelator-inaccessible mechanism:
biological and clinical implications, Am. J. Physiol. Cell Physiol. 293 (2007)
C1383–C1394.
[37] P.R. Anderson, K. Kirby, A.J. Hilliker, J.P. Phillips, RNAi-mediated
suppression of the mitochondrial iron chaperone, frataxin, in Drosophila,
Hum. Mol. Genet. 14 (2005) 3397–3405.
[38] C. Fosset, M.J. Chauveau, B. Guillon, F. Canal, J.C. Drapier, C. Bouton,
RNA silencing of mitochondrial m-Nfs1 reduces Fe–S enzyme activity
both in mitochondria and cytosol of mammalian cells, J. Biol. Chem. 281
(2006) 25398–25406.
[39] G. Kispal, K. Sipos, H. Lange, Z. Fekete, T. Bedekovics, T. Janaky, J.
Bassler, D.J. Aguilar Netz, J. Balk, C. Rotte, R. Lill, Biogenesis of
cytosolic ribosomes requires the essential iron–sulphur protein Rli1p and
mitochondria, EMBO J. 24 (2005) 589–598.
[40] O. Gakh, S. Park, G. Liu, L. Macomber, J.A. Imlay, G.C. Ferreira, G. Isaya,
Mitochondrial iron detoxification is a primary function of frataxin thatlimits oxidative damage and preserves cell longevity, Hum. Mol. Genet. 15
(2006) 467–479.
[41] A.L. Bulteau, A. Dancis, M. Gareil, J.J. Montagne, J.M. Camadro, E.
Lesuisse, Oxidative stress and protease dysfunction in the yeast model of
Friedreich ataxia, Free Radic. Biol. Med. 42 (2007) 1561–1570.
[42] S. Park, O. Gakh, S.M. Mooney, G. Isaya, The ferroxidase activity of yeast
frataxin, J. Biol. Chem. 277 (2002) 38589–38595.
[43] G. Tan, L.S. Chen, B. Lonnerdal, C. Gellera, F.A. Taroni, G.A. Cortopassi,
Frataxin expression rescues mitochondrial dysfunctions in FRDA cells,
Hum. Mol. Genet. 10 (2001) 2099–2107.
[44] V.C.Culotta,M.Yang, T.V.O’Halloran, Activation of superoxide dismutases:
putting themetal to the pedal, Biochim. Biophys. Acta 1763 (2006) 747–758.
[45] R.O. Morgan, G. Naglie, D.F. Horrobin, A. Barbeau, Erythrocyte proto-
porphyrin levels in patients with Friedreich's and other ataxias, Can. J.
Neurol. Sci. 6 (1979) 227–232.
[46] T. Yoon, J.A. Cowan, Frataxin-mediated iron delivery to ferrochelatase in the
final step of heme biosynthesis, J. Biol. Chem. 279 (2004) 25943–25946.
